Omnicell (OMCL) Cash from Investing Activities (2010 - 2026)
Omnicell's (OMCL) quarterly Cash from Investing Activities came in at -$12.5 million in Q2 2026, up 21.3% year-over-year from -$10.3 million in Q2 2025, and up 21.02% quarter-over-quarter from -$15.9 million in Q1 2026.
Analysis
Omnicell (OMCL) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Omnicell (OMCL) has reported Cash from Investing Activities for 17 consecutive years, with -$12.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Investing Activities rose 21.3% year-over-year to -$12.5 million in Q2 2026; TTM through Jun 2026 was -$57.1 million, a 2.5% increase from a year earlier, with the FY2025 full-year figure at -$60.4 million, down 14.34% from the prior year.
- Cash from Investing Activities was -$12.5 million for Q2 2026 at Omnicell, up from -$15.9 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$6.8 million in Q2 2022 and troughed at -$18.7 million in Q1 2022.
- A 5-year average of -$14.2 million and a median of -$14.2 million in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities soared 91.81% in 2022 and tumbled 117.35% in 2023, its largest moves.
- Over 5 years, Cash from Investing Activities stood at -$17.3 million in 2022, then increased by 28.29% to -$12.4 million in 2023, then fell by 9.67% to -$13.6 million in 2024, then decreased by 6.28% to -$14.4 million in 2025, then climbed by 13.1% to -$12.5 million in 2026.
- The last three Cash from Investing Activities figures came in at -$12.5 million (Q2 2026), -$15.9 million (Q1 2026), and -$14.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | -673.00 Mn |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | -26.60 Mn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | -1.62 Bn |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | -639.00 Mn |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | -1.96 Bn |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | -193.20 Mn |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | -222.00 Mn |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | 329.80 Mn |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | -383.65 Mn |
| 10 | Omnicell | 1.57 Bn | 1.28 Bn | 152.94 Mn | -12.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.53 Mn |
| Mar 31, 2026 | -15.87 Mn |
| Dec 31, 2025 | -14.42 Mn |
| Sep 30, 2025 | -14.28 Mn |
| Jun 30, 2025 | -15.92 Mn |
| Mar 31, 2025 | -15.74 Mn |
| Dec 31, 2024 | -13.57 Mn |
| Sep 30, 2024 | -13.34 Mn |
| Jun 30, 2024 | -13.55 Mn |
| Mar 31, 2024 | -12.34 Mn |
| Dec 31, 2023 | -12.37 Mn |
| Sep 30, 2023 | -14.19 Mn |
| Jun 30, 2023 | -14.82 Mn |
| Mar 31, 2023 | -13.64 Mn |
| Dec 31, 2022 | -17.25 Mn |
| Sep 30, 2022 | -15.87 Mn |
| Jun 30, 2022 | -6.82 Mn |
| Mar 31, 2022 | -18.73 Mn |
| Dec 31, 2021 | -192.39 Mn |
| Sep 30, 2021 | -193.63 Mn |